Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.32 |
| ▸ | GAA | P10253 | 2/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | POLA1 | P09884 | 1/20 | 0.31 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.31 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.31 |
| ▸ | CCR2 | P41597 | 1/20 | 0.30 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
| ▸ | CNR2 | P34972 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6695866 | 1.00 | NPC1 (0.33) | NPC1RAB9AMAPK1GAATHRB | |
| SCHEMBL6670947 | 1.00 | NPC1 (0.33) | NPC1RAB9AMAPK1GAATHRB | |
| SCHEMBL6691688 | 0.84 | POLA1 (0.36) | RAB9ATHRBLMNAKMT2AMAPT | |
| SCHEMBL6691685 | 0.84 | POLA1 (0.36) | RAB9ATHRBLMNAKMT2AMAPT | |
| SCHEMBL6669028 | 0.84 | MAPK1 (0.39) | MAPK1GAAALDH1A1KMT2AMAPT | |
| SCHEMBL6690714 | 0.83 | LMNA (0.37) | NPC1RAB9AMAPK1GAATHRB | |
| SCHEMBL6672153 | 0.83 | EPHX1 (0.33) | NPC1RAB9AMAPK1GAATHRB | |
| SCHEMBL6672157 | 0.83 | EPHX1 (0.33) | NPC1RAB9AMAPK1GAATHRB | |
| SCHEMBL6667328 | 0.83 | MAPK1 (0.37) | MAPK1GAALMNAALDH1A1KMT2A | |
| SCHEMBL6669484 | 0.82 | MAPK1 (0.36) | MAPK1GAAKMT2APOLA1EGLN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040067947-A1 | Method of preventing or treating atherosclerosis or restenosis | WATHEN MICHAEL W | 2004-04-08 | — | — | US | claimed |
| WO-2004019940-A1 | METHOD OF PREVENTING OR TREATING ATHEROSCLEROSIS OR RESTENOSIS | PHARMACIA & UPJOHN COMPANY (US) | 2004-03-11 | — | — | WO | claimed |
| EP-1265872-A1 | 4-HYDROXYCINNOLINE-3-CARBOXYAMIDES AS ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2002-12-18 | — | — | EP | claimed |
| US-6458788-B1 | VIRICIDES; HERPES VIRUS | PHARMACIA & UPJOHN COMPANY | 2002-10-01 | — | — | US | claimed |
| US-20020042397-A1 | 4-hydroxycinnoline-3-carboxyamides as antiviral agents | PHARMACIA & UPJOHN COMPANY | 2002-04-11 | — | — | US | claimed |
| WO-2001081318-A1 | 4-HYDROXYCINNOLINE-3-CARBOXYAMIDES AS ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2001-11-01 | — | — | WO | claimed |
| US-20040067947-A1 | Method of preventing or treating atherosclerosis or restenosis | WATHEN MICHAEL W | 2004-04-08 | — | — | US | disclosed |
| US-6458788-B1 | VIRICIDES; HERPES VIRUS | PHARMACIA & UPJOHN COMPANY | 2002-10-01 | — | — | US | disclosed |
| US-20020042397-A1 | 4-hydroxycinnoline-3-carboxyamides as antiviral agents | PHARMACIA & UPJOHN COMPANY | 2002-04-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020042397-A1 | 4-hydroxycinnoline-3-carboxyamides as antiviral agents | HAVCR2, ZC3HAV1, HCFC1 | NPC1 498/4885RAB9A 3147/4885MAPK1 4363/4885 |
| US-20040067947-A1 | Method of preventing or treating atherosclerosis or restenosis | LDLR, MSR1, NR1H2 | NPC1 88/4885RAB9A 1437/4885MAPK1 737/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.